Medibact GuidesShop at Medibact

CJC-1295 Dosage: DAC vs No-DAC Figures and Units per Vial

The two human CJC-1295 studies used the DAC form at 30 to 90 mcg/kg. This page reports them, the vendor figures for both forms, and the units per vial.

Medibact Guides · Published 2026-09-18

Illustration: A clear glass vial with pale blue liquid on a white surface, lit by natural light.
Illustration

CJC-1295 is the compound where a reader most needs to know which molecule a figure refers to, because the name covers two. The one with a Drug Affinity Complex, the DAC, is the molecule the two human studies used, at per-kilogram doses given once or weekly. The one without it, sold as "no DAC" and as Mod GRF 1-29, has no human study and a completely different dosing convention, in micrograms several times a day. This page reports both sets of figures as their sources state them, keeps them apart, and works the units for the 5 mg and 10 mg vials the site's calculator uses.

CJC-1295 is a 29-amino-acid analogue of the active fragment of growth-hormone-releasing hormone with four amino-acid substitutions; in the DAC version a maleimidopropionic-acid group lets it bind albumin in the blood, which is what stretches its half-life to about a week. Medibact's CJC-1295 guide covers the molecule, the two forms and their evidence; this page stays with figures. The dosage hub lists every compound's page; the CJC-1295 + Ipamorelin page covers the blend.

What the sources state

Source Kind Form Figure Date read
DailyMed search, "CJC-1295" Label search Both Zero records; no approved product 2026-09-18
Teichman et al., JCEM 2006 (PMID 16352683) Trial publication DAC Four ascending single subcutaneous doses in study 1; two or three weekly or biweekly doses in study 2; "particularly at doses of 30 or 60 microg/kg"; healthy adults 21 to 61; half-life 5.8 to 8.1 days 2026-09-18
Ionescu and Frohman, JCEM 2006 (PMID 17018654) Trial publication DAC Single injection of 60 or 90 microg/kg; healthy men 20 to 40; pulsatile GH persisted 1 week; half-life 8 days 2026-09-18
NCT00267527, ConjuChem, phase 2, HIV visceral obesity Trial protocol DAC Started December 2005; terminated; no dose posted 2026-09-18
Vendor and protocol pages (two opened) Commonly cited DAC 1 to 2 mg per week, once weekly or 500 to 1,000 mcg twice weekly; also 300 to 1,000 mcg twice weekly, 0.6 to 2 mg a week, 8 to 12 weeks; 500 mcg once weekly as a first figure 2026-09-18
Vendor and protocol pages (two opened) Commonly cited No DAC 100 to 200 mcg two to three times a day; 100 to 300 mcg once daily before bed; 200 to 600 mcg a day in total; "100 mcg is often considered the saturation dose" 2026-09-18

The DAC trial doses and the DAC vendor doses are not on the same scale. Thirty mcg/kg is 2.1 mg at 70 kg for one injection; the vendor pages' whole week is 1 to 2 mg. The trials were looking for the dose that raised IGF-1 for a fortnight; the vendor figures are a market's smaller convention, and the two should not be read as agreeing.

The per-kilogram figures in milligrams

Because the trials report doses per kilogram and vials are labelled in milligrams, the conversion is worth showing, with the caveat that it is this page's arithmetic and not the papers'. At 60 kg, 70 kg and 80 kg, 30 mcg/kg is 1.8, 2.1 and 2.4 mg; 60 mcg/kg is 3.6, 4.2 and 4.8 mg; 90 mcg/kg is 5.4, 6.3 and 7.2 mg. A 5 mg vial holds two of the 30 mcg/kg amounts at 70 kg and one of the 60 mcg/kg amounts; a 10 mg vial holds four and two. The abstract of the first study says four ascending single doses were given and names only the two it found most useful; the full list is in the paper's methods, which were not opened for this page, so only the abstract's figures appear here.

Units per dose at each research-vial size

Research-market CJC-1295 is supplied in 5 mg and 10 mg vials, and the arithmetic is the same for both forms: the vial amount divided by the water added gives the concentration, and the amount drawn divided by the concentration gives the volume, at 100 units per mL on a U-100 syringe (MedlinePlus, read 2026-09-18); the site's insulin syringe units page covers the syringe reading itself. The table converts the no-DAC vendor figures (100, 200 and 300 mcg), the DAC vendor figures (1 and 2 mg) and the trials' 30 mcg/kg at 70 kg (2.1 mg).

Vial Water added Concentration 100 mcg 200 mcg 300 mcg 1 mg 2 mg 2.1 mg
5 mg 1 mL 5 mg/mL 2 4 6 20 40 42
5 mg 2 mL 2.5 mg/mL 4 8 12 40 80 84
5 mg 3 mL 1.67 mg/mL 6 12 18 60 120 (>1 syringe) 126 (>1 syringe)
10 mg 1 mL 10 mg/mL 1 2 3 10 20 21
10 mg 2 mL 5 mg/mL 2 4 6 20 40 42
10 mg 3 mL 3.33 mg/mL 3 6 9 30 60 63

The two forms pull the water volume in opposite directions. A microgram draw at 10 mg/mL is a single unit, too small to read with confidence, so the no-DAC convention adds water; a milligram draw at 1.67 mg/mL overflows a 1 mL syringe, so the DAC convention keeps the concentration up. The CJC-1295 calculator works any combination entered; the site's CJC-1295 reconstitution page covers water volumes per vial and the mixing steps as references describe them; and the Mod GRF 1-29 calculator is the same arithmetic under the no-DAC molecule's other name.

What the figures omit

The trial figures carry a population (healthy adults, healthy young men), a route, a single or fortnightly schedule and a follow-up of days to weeks; they carry no course length, because the studies ended. The terminated phase 2 carries a disease population and nothing else public. The DAC vendor figures carry a weekly rhythm and an 8-to-12-week course with no source for the course; the no-DAC figures carry a daily rhythm, a timing rule (before bed, fasted) and the word "saturation", for which no human dose-response study exists. None of the rows states what a blend with ipamorelin changes, and none says which form a given vial holds; that is on the vial's own documentation, and this site's calculator note says the same.

What this page does not do

This page reports figures with their sources and dates and converts them into syringe units at the site's vial sizes. It does not recommend a dose, a form, a frequency or a course for anyone, and it does not turn the vendor conventions into advice. The mixing steps and the storage of a mixed vial are the store's topics: how to reconstitute peptides and how to store peptides on medibact.com.

Sources and dates

Opened 2026-09-18: the DailyMed SPL search API for "CJC-1295" (zero records); PubMed through the NCBI E-utilities for the abstracts of PMIDs 16352683 and 17018654; the ClinicalTrials.gov v2 API for "CJC-1295" (one record, NCT00267527); two vendor and protocol pages carrying dated DAC and no-DAC figures (a third, a national pharmacy chain's peptide page, returned HTTP 403 and was not read); PubChem was not needed; and MedlinePlus for the U-100 definition. The full text of the 2006 JCEM papers was not opened, so the four single-dose levels of the first study are not listed here. Corrections go to the contact page.

Frequently asked questions

What is the CJC-1295 dosage with DAC?

The two human studies gave single subcutaneous doses of 30 to 90 mcg/kg, about 2.1 to 6.3 mg at 70 kg, and in one study repeated 30 or 60 mcg/kg weekly or every two weeks (Teichman 2006; Ionescu 2006, abstracts read 2026-09-18). Vendor pages read the same day state 1 to 2 mg a week, once weekly or split twice weekly. The trial doses are per-kilogram figures in a study setting; the vendor figures are fixed milligram amounts that sit below them. No label exists.

What is the CJC-1295 dosage without DAC?

There is no trial figure at all. The no-DAC molecule, sold as Mod GRF 1-29, has no human study in the indexed literature; both human CJC-1295 papers used the DAC form. Vendor pages read on 2026-09-18 state 100 to 300 mcg per injection, one to three times a day, and describe 100 mcg as a saturation dose. Those figures are a market convention with a pharmacological rationale (a short-acting GHRH analogue given in pulses) but no dose-finding study behind them.

How many units is 2 mg of CJC-1295 DAC?

At 2.5 mg/mL, which a 5 mg vial reaches with 2 mL of water, 2 mg is 0.8 mL, or 80 units on a U-100 syringe. At 5 mg/mL (a 5 mg vial with 1 mL or a 10 mg vial with 2 mL) it is 40 units; at 10 mg/mL it is 20 units; at 1.67 mg/mL it is 120 units, more than one syringe. The 1 mg figure is half of each. The table on this page works both vial sizes at 1, 2 and 3 mL.

How many units is 100 mcg of CJC-1295 no DAC?

At 2.5 mg/mL (5 mg vial, 2 mL) 100 mcg is 0.04 mL, or 4 units. At 5 mg/mL it is 2 units and at 10 mg/mL 1 unit, the smallest mark on a U-100 syringe, which is why vendor pages add more water for microgram amounts: at 1.67 mg/mL (5 mg vial, 3 mL) 100 mcg is 6 units, and 300 mcg is 18 units. Larger draws are easier to read; the amount does not change.

Is there a CJC-1295 dosage chart?

The table on this page is one. It takes the 5 mg and 10 mg vials at 1, 2 and 3 mL and converts 100, 200 and 300 mcg (the no-DAC vendor figures), 1 mg and 2 mg (the DAC vendor figures) and 2.1 mg (the trials' 30 mcg/kg at 70 kg) into syringe units. The one thing a chart cannot show is which molecule is in the vial; the arithmetic is identical for both, and the label on the vial is the only authority on that.

What is the CJC-1295 protocol in the trials?

Teichman 2006 ran two studies in healthy adults: single ascending subcutaneous doses, and then two or three doses given weekly or every two weeks, with growth hormone and IGF-1 raised for days to weeks and a half-life estimated at 5.8 to 8.1 days. Ionescu 2006 gave one dose of 60 or 90 mcg/kg and watched pulsatile secretion continue for a week. That is the whole human record. The 8-to-12-week courses on vendor pages appear in neither paper.